Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program - 12/09/11
Doi : 10.1016/S0090-4295(99)80255-6
Michael J. Barry, M.D. a, b, c, d, e, ⁎, Craig Fleming, M.D. a, b, c, d, e, Christopher M. Coley, M.D. a, b, c, d, e, John H. Wasson, M.D. a, b, c, d, e, Marianne C. Fahs, Ph.D.M.P.H. a, b, c, d, e, Joseph E. Oesterling, M.D. a, b, c, d, e
a From the Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA
b Health Outcomes Associates, Vancouver, Washington, USA
c From the Center for the Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, New Hampshire, USA
d From the Division of Health Economics, Department of Community Medicine, and the International Longevity Center (US), Mount Sinai School of Medicine, New York, New York, USA
e From the Division of Urology, Department of Surgery, The University of Michigan, Ann Arbor, Michigan, USA
*Reprint requests: Michael J. Barry, M.D., Department of Medical Practices Evaluation Center, Massachusetts General Hospital, 50 Stanford Street, 9th Floor, Boston, MA 02114.
| * | This study was supported by grant HS 06336 and 08397 from the Agency for Health Care Policy and Research, and contract K3-0546.0 from the Office of Technology Assessment, Congress of the United States. The conclusions are solely those of the authors and do not represent the views of the Office of Technology Assessment, the Technology Assessment Board, or the US Congress. |
© 1997
Publié par Elsevier Masson SAS.
Vol 46 - N° 4
P. 445-461 - octobre 1995 Retour au numéro
Article suivant
- Hemospermia: diagnosis and management
- John E. Mulhall, Peter C. Albertsen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?